Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?

World Journal of Clinical Oncology
Pedro Bargão SantosAna Félix

Abstract

Prostate cancer (PCa) is a highly prevalent malignancy and constitutes a major cause of cancer-related morbidity and mortality. It emerges through the acquisition of genetic and epigenetic alterations. Epigenetic modifications include DNA methylation, histone modifications and microRNA deregulation. These generate heritable transformations in the expression of genes but do not change the DNA sequence. Alterations in DNA methylation (hypo and hypermethylation) are the most characterized in PCa. They lead to genomic instability and inadequate gene expression. Major and minor-specific modifications in chromatin recasting are involved in PCa, with signs suggesting a dysfunction of enzymes modified by histones. MicroRNA deregulation also contributes to the initiation of PCa, including involvement in androgen receptor signalization and apoptosis. The influence of inflammation on prostate tumor carcinogenesis is currently much better known. Recent discoveries about microbial species resident in the urinary tract suggest that these are the initiators of chronic inflammation, promoting prostate inflammatory atrophy and eventually leading to PCa. Complete characterization of the relationship between the urinary microbiome and prostatic c...Continue Reading

References

Dec 14, 1999·The American Journal of Pathology·A M De MarzoW G Nelson
Aug 11, 2001·Science·T Jenuwein, C D Allis
Jul 9, 2002·Urology·Leslie K DennisJames C Torner
Apr 23, 2003·The American Journal of Pathology·Geert J L H van LeendersAngelo M De Marzo
Jul 25, 2003·The New England Journal of Medicine·William G NelsonWilliam B Isaacs
Jan 21, 2004·Nature Reviews. Cancer·Andrew P Feinberg, Benjamin Tycko
Mar 1, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tarja AnttilaMatti Hakama
Jul 16, 2005·Scandinavian Journal of Urology and Nephrology. Supplementum·Mahul AminRodolfo Montironi
Jul 26, 2005·Molecular Cell·Jane Mellor
Dec 22, 2005·Nature Reviews. Genetics·Andrew P FeinbergSteven Henikoff
May 17, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Siobhan SutcliffeElizabeth A Platz
Jan 3, 2007·Prostate Cancer and Prostatic Diseases·E V VykhovanetsS Gupta
Feb 27, 2007·Cell·Tony Kouzarides
Mar 27, 2007·Nature Reviews. Cancer·Angelo M De MarzoWilliam G Nelson
Aug 9, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Siobhan SutcliffeElizabeth A Platz
Nov 7, 2007·Nature Structural & Molecular Biology·Sukesh R BhaumikAli Shilatifard
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Sep 5, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Wen-Yi HuangCharles S Rabkin
Oct 7, 2008·The International Journal of Biochemistry & Cell Biology·Sònia Guil, Manel Esteller
Jan 27, 2009·Biochimica Et Biophysica Acta·Andreas Lennartsson, Karl Ekwall
Feb 7, 2009·Health Technology Assessment : HTA·G RogersM Somerville
Mar 20, 2009·The New England Journal of Medicine·Gerald L AndrioleUNKNOWN PLCO Project Team
Jun 23, 2009·Cancer·Alessia Lopergolo, Nadia Zaffaroni
Jul 28, 2009·Annual Review of Medicine·Ramiro GarzonCarlo M Croce
Sep 10, 2009·The Prostate·Jörg EllingerAlexander von Ruecker
Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Dec 17, 2009·Cancer Metastasis Reviews·Sylvia K Shenouda, Suresh K Alahari
Mar 5, 2010·CA: a Cancer Journal for Clinicians·Andrew M D WolfUNKNOWN American Cancer Society Prostate Cancer Advisory Committee
Apr 7, 2010·The American Journal of Pathology·May KhaliliCharles J Bieberich
May 5, 2010·Nature Reviews. Clinical Oncology·Peter C Albertsen
Jul 6, 2010·Nature Genetics·Michael C HaffnerSrinivasan Yegnasubramanian
Dec 9, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ewa DudziecJames W F Catto
Feb 8, 2011·European Urology·James W F CattoTapio Visakorpi
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Mar 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael C HaffnerSrinivasan Yegnasubramanian
May 24, 2011·European Urology·Guillaume PloussardTheodorus H van der Kwast
Dec 21, 2011·Prostate Cancer and Prostatic Diseases·G GueronE Vazquez

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
biopsy
biopsies

Software Mentioned

MiRNA

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.